Sorin Group S.p.A. (SRN) Announces FDA Approval and Commercial Launch of Complete Portfolio of Implantable Heart Device Leads
5/10/2012 10:27:47 AM
New pacing, defibrillation and left ventricular leads, combined with Sorin Group’s innovative implantable devices enable effective management of arrhythmias and heart failure
Heart Rhythm 2012
BOSTON--(BUSINESS WIRE)--Sorin Group, (Reuters Code: SORN.MI), a global medical device company and a leader in the treatment of cardiovascular diseases, announced today at Heart Rhythm 2012, the Heart Rhythm Society’s 33rd Annual Scientific Sessions, FDA approval and commercial launch for a full portfolio of pacing, defibrillation and left ventricular leads. Designed for effective electrical performance and durability, each of the three lead series – TILDA pacing leads, VIGILA defibrillation leads and CELERITY left ventricular leads – include multiple sizes and features to enable physicians to match their implant preferences with individual patient needs.
In addition to a flexible silicone lead body, steroid eluting tips that reduce inflammation, and iridium fractal coated electrodes with proven electrical performance1, each lead family offers its own additional features:
TILDA pacing leads include a flexible lead body and distal tip and are designed for easy implantation and predictable performance.
VIGILA defibrillation leads feature a symmetrical lead body and thick outer insulation. Convex shock coils embedded in silicone insulation are engineered to minimize tissue in-growth.
CELERITY left ventricular leads have a flexible co-radial body, and are designed to facilitate access and ensure stability in targeted pacing sites regardless of patients’ coronary venous anatomies.
“Sorin Group is bringing important new implantable heart rhythm and heart failure systems to the United States, an important and growing market for Sorin Group. The VIGILA, TILDA and CELERITY leads are important additions that will help the U.S. physicians manage their patients,” said Stefano Di Lullo, Sorin Group, President of the CRM Business Unit. “We’ve received tremendous feedback from physicians in other international markets about the reliability of these leads, and we are committed to continuing to deliver outstanding technologies to enhance clinical performance and patient outcomes in the United States and throughout the world.”
About Sorin Group
Sorin Group (www.sorin.com) is a global, medical device company and a leader in the treatment of cardiovascular diseases. The Company develops, manufactures, and markets medical technologies for cardiac surgery and for the treatment of cardiac rhythm disorders. With 3,750 employees worldwide, Sorin Group focuses on three major therapeutic areas: cardiopulmonary bypass (extracorporeal circulation and autotransfusion systems), cardiac rhythm management, and heart valve repair and replacement. Every year, over one million patients are treated with Sorin Group devices in more than 80 countries.
For more information, please visit www.sorin.com.
Martine Konorski, +33 (0)1 46 01 33 78
Mobile: +33 (0)6 76 12 67 73
Director, Corporate Communications
Francesca Rambaudi, +39 02 69969716
Director, Investor Relations